论文部分内容阅读
目的:观察不同剂量吡柔比星治疗急性髓系白血病的临床疗效。方法:选择急性髓系白血病患者100例,随机分为对照组和观察组各50例,均给予TA方案治疗。对照组吡柔比星剂量为20mg/d,观察组吡柔比星剂量为40mg/d。连续治疗2个疗程,观察并比较两组患者临床疗效和不良反应的差异。结果:与对照组比较,观察组总有效率和不良反应发生率均明显较高,差异均具有统计学意义(P<0.05)。结论:采用大剂量吡柔比星治疗急性髓系白血病,可以取得较满意的临床疗效,但同时不良反应也较大,在临床应用时应根据具体病情权衡使用剂量。
Objective: To observe the clinical efficacy of different doses of pirarubicin in the treatment of acute myeloid leukemia. Methods: 100 patients with acute myeloid leukemia were randomly divided into control group and observation group of 50 cases, were given TA regimen. The control group, the dose of pirarubicin 20mg / d, the observation group pirarubicin dose 40mg / d. Continuous treatment of 2 courses, observed and compared the two groups of patients with clinical efficacy and adverse reaction. Results: Compared with the control group, the total effective rate and the incidence of adverse reactions in the observation group were significantly higher, the differences were statistically significant (P <0.05). Conclusion: The high dose of pirarubicin in the treatment of acute myeloid leukemia, can achieve more satisfactory clinical efficacy, but also larger adverse reactions, the clinical application should be based on the specific condition to weigh the use of dose.